Thursday, April 18, 2019 1:30:45 PM
13:07 0.94 0.96 0.7701 0.7864 2,165,744*
04/17/2019 0.85 0.85 0.81 0.83 28,543
04/16/2019 0.8241 0.85 0.80 0.82 36,216
04/15/2019 0.8342 0.86 0.82 0.8306 50,967
04/12/2019 0.84 0.8597 0.83 0.8595 26,977
04/11/2019 0.87 0.87 0.83 0.84 42,651
04/10/2019 0.87 0.8846 0.86 0.861 104,827
04/09/2019 0.90 0.90 0.85 0.8897 99,365
04/08/2019 0.90 0.9075 0.8802 0.89 47,966
04/05/2019 0.9198 0.9198 0.8902 0.9054 64,497
04/04/2019 0.90 0.92 0.872 0.90 95,195
04/03/2019 0.8896 0.89 0.8606 0.872 39,811
04/02/2019 0.89 0.8999 0.86 0.8896 41,339
04/01/2019 0.892 0.92 0.88 0.88 52,159
03/29/2019 0.93 0.93 0.8862 0.915 37,999
03/28/2019 0.91 0.93 0.8798 0.8896 48,572
03/27/2019 0.93 0.93 0.88 0.8849 47,471
03/26/2019 0.92 0.9712 0.8901 0.93 141,943
03/25/2019 0.941 1.01 0.9402 0.98 59,188
03/22/2019 1.01 1.01 0.942 0.9859 40,672
03/21/2019 1.03 1.03 0.96 0.97 39,602
03/20/2019 1.0101 1.0396 1.01 1.01 18,411
03/19/2019 1.02 1.03 0.9761 1.00 89,964
MAPS
Recent SNGX News
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa • PR Newswire (US) • 04/25/2024 11:30:00 AM
- Soligenix Announces Pricing of $4.75 Million Public Offering • PR Newswire (US) • 04/18/2024 12:30:00 PM
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection • PR Newswire (US) • 04/15/2024 11:30:00 AM
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection • PR Newswire (US) • 04/11/2024 11:30:00 AM
- Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency • PR Newswire (US) • 04/03/2024 11:30:00 AM
- Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results • PR Newswire (US) • 03/15/2024 11:30:00 AM
- Soligenix Announces Formation of Behçet's Disease Medical Advisory Board • PR Newswire (US) • 02/08/2024 12:30:00 PM
- Soligenix to Present at The Microcap Conference • PR Newswire (US) • 01/25/2024 12:30:00 PM
- FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease • PR Newswire (US) • 01/08/2024 12:30:00 PM
- Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis • PR Newswire (US) • 01/04/2024 12:30:00 PM
- Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses • PR Newswire (US) • 01/02/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:05:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/18/2023 05:15:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:03:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:12:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:11:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:10:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:10:16 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/08/2023 09:05:59 PM
- "HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery • PR Newswire (US) • 12/01/2023 12:30:00 PM
- Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease • PR Newswire (US) • 11/30/2023 12:30:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM